Clinical Trials Logo

Clinical Trial Summary

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.


Clinical Trial Description

Study Drug Indication: - Treatment of HRV infections in patients with COPD Study Rationale: An effective, easily administered therapy for RV infection would have the potential to reduce the serious health effects in vulnerable populations, such as those with COPD. Treatment of RV infection could reduce the severity and frequency of acute COPD exacerbations, preserve pulmonary function, prevent secondary bacterial infections, and mitigate the need for costly medical interventions, including inhaled agents, steroids, antibacterial drugs, emergency treatment, hospitalization, and mechanical ventilation. Thus, early treatment of acute COPD exacerbations related to RV infection could potentially improve both the quality of life and longevity of COPD patients. Altesa BioSciences, Inc. is developing drugs to treat RV and other respiratory virus infections. VPV has been shown to inhibit RV in vitro and in human clinical trials. Furthermore, VPV has been administered to more than 650 study participants and has been well-tolerated. Based on its potential to prevent severe respiratory complications, Altesa BioSciences, Inc is continuing the development of this drug for the treatment of RV infection. Study Dose justification: - In patients with asthma, vapendavir doses of 264 mg bid and 528 mg bid were utilized and demonstrated reduced viral load and was well tolerated. - A PK study established the pharmacokinetics of a free based micronized tablet in achieving adequate plasma levels after a single dose in fed adults. Study Treatment Duration: - 7 days End of Study: - Up to 63 days, including the screening and follow-up periods. Study Centers: - There will be 1 study centre, ICRRU within Imperial College Healthcare NHS site at St Mary's Hospital London, United Kingdom. Study Treatment: - 1:1 randomization to Vapendavir 500mg bid or placebo Study Procedures: - Screening period (Pregnancy test for females, Lung function tests (FEV1, FVC, PEF), Height and Weight/BMI Calculation, Physical Examination, Vital Signs, Medical and Surgical history, Blood sample, COPD assessment test) - Baseline visit to clinic (Pregnancy test for females, Physical examination, Safety assessments, Vital Signs, Concomitant medication assessment, Nasal lavage/nasosorption, Chest X-Ray, ECG, Blood for hematology, biochemistry and liver function tests, Induced Sputum, Lung Function Tests (FEV1, FVC, PEF)) - Clinical Visit Day 1 (Randomization to treatment, Dispense Medication, Physical Examination, Safety Assessments, Vital Signs, Concomitant medication assessment, Nasal lavage/nasosorption, Chest X-Ray, ECG, Blood for hematology, biochemistry and liver function tests, Induced Sputum, Lung Function Tests (FEV1, FVC, PEF), Intranasal RV-A16 challenge) - Treatment Commencement-Clinical Visit Days 1-28 (Physical Exam, Safety Assessments, Vital Signs, Concomitant Medication and food assessments, Diaries and eCRF completion, Treatment twice daily (If required), Drug Compliance, Nasal Lavage/nasosorption, Blood serum for biomarkers, Blood for hematology and biochemistry, Blood for PK, Pregnancy test for females, Lung Function Tests (FEV1, FVC, PEF)) - Treatment Commencement-Clinical Visit Day 42 (Physical Examination, Safety Assessments, Vital Signs, Concomitant medication and food assessments, Diaries and eCRF completion, Nasal lavage/nasosorption, Blood serum for biomarkers, blood for hematology, biochemistry and liver function tests, Blood sample taken to assess RV-A16 sero-positivity, Pregnancy test for females, Lung Function Tests (FEV1, FVC, PEF)) - Early Termination Visit (Physical Examination, Safety Assessments, Vital Signs, Concomitant medication and food assessments, Diaries and eCRF completion, Nasal lavage/nasosorption, Blood Serum for Biomarkers, Blood for hematology and biochemistry, Blood for PK, Sputum - Unscheduled Visit (Physical Examination, Safety Assessments, Vital Signs, Concomitant medication and food assessments, Diaries and eCRF completion, Drug complicance, Lung function tests (FEV1, FVC, PEPF), Blood or PK-morning (or sampling)) - Study drug administered as soon as possible after onset of symptoms and documentation of HRV infection, but no greater than 48 hours after symptom onset. Study Sample Size: • 50 participants randomization will be 1:1 VPV : placebo. Participants will undergo 7 days of twice daily treatment. Treatment will commence after symptom onset or when the participant determines they have a clinical cold. Statistical Methods: - Efficacy Analysis: All participants infected and treated will comprise the infected and evaluable population and be included in the efficacy analysis (primary, secondary, exploratory endpoints). Subjects inoculated but not successfully infected will not be included in this analysis. - Safety Analysis: All participants that have undergone any treatment with VPV or placebo will comprise the safety population and will be included in the safety analysis. Subjects that are inoculated, treated but not successfully infected will be included in this population. - Inoculated & Followed-Up Population: Participants that are inoculated, but that do not fit the criteria to undergo treatment or become pregnant will be followed up until Day 42 ± 2. This group will be composed of both uninfected and successfully infected participants and follow up will be to obtain data on the RV challenge model, COPD related symptoms and also for safety reasons. - Statistical Analysis Plan: A comprehensive Statistical Analysis Plan (SAP) will be finalized prior to reporting of the study results. The SAP may modify the plans outlined in the protocol; however, any major modifications of planned analyses will be reflected in a protocol amendment. ;


Study Design


Related Conditions & MeSH terms

  • Acute Disease
  • Chronic Respiratory Disease
  • Common Cold
  • Communicable Diseases
  • Copd
  • COPD Exacerbation Acute
  • Emphysema
  • Emphysema or COPD
  • Enterovirus
  • Enterovirus Infections
  • Infection Viral
  • Infections
  • Infections, Respiratory
  • Lower Respiratory Disease
  • Lower Respiratory Tract and Lung Infections
  • Lung Disease Chronic
  • Lung Diseases
  • Lung Diseases, Obstructive
  • Obstructive Pulmonary Disease
  • Pulmonary Disease
  • Pulmonary Disease, Chronic Obstructive
  • Respiration Disorders
  • Respiratory Complication
  • Respiratory Disease
  • Respiratory Tract Diseases
  • Respiratory Tract Infections
  • Respiratory Viral Infection
  • Rhinovirus
  • Rhinovirus Infection
  • RNA Virus Infections
  • Upper Resp Tract Infection
  • Upper Respiratory Disease
  • Upper Respiratory Tract Infections
  • Viral Infection
  • Virus Diseases

NCT number NCT06149494
Study type Interventional
Source Altesa Biosciences, Inc.
Contact Jeffrey Bruno
Phone 7329866236
Email jbruno@altesa.com
Status Recruiting
Phase Phase 2
Start date November 20, 2023
Completion date March 30, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A